
Coherus Oncology, Inc.
91
Recent developments include the release of third quarter 2026 financial results, announcement of a strategic prioritization plan, ongoing clinical trial progress in esophageal cancer therapies, and issuance of a special dividend related to biosimilar CVRs.
- Coherus Oncology reported third quarter 2026 financial results including a net loss of $39.3 million and announced a strategic prioritization plan [N1].
- The company reported a Q3 2026 loss and revenue below expectations [N2].
- Clinical data showed a 75% confirmed overall response rate in first-line esophageal squamous cell carcinoma patients from Tagmokitug interim data [N1].
- An 89% response rate was reported in an early esophageal squamous cell carcinoma study [N1].
- Coherus initiated a Phase 1 trial of ZM008 and LOQTORZI combination with Zumutor [N7].
- The company issued a special dividend related to biosimilar contingent value rights (CVRs) [N6].
Coherus Oncology, Inc. operates in the biopharmaceutical sector with a focus on oncology drug development. The company is engaged in clinical trials for cancer therapies, including immuno-oncology agents and biosimilars. It has reported ongoing net losses in recent quarters and maintains liquidity through cash and short-term investments. The company announced a strategic prioritization plan in late 2026 and continues to advance clinical programs, including combination therapies in esophageal cancer.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Coherus Oncology, Inc. is a biopharmaceutical company focused on oncology, reporting a net loss of $39.3 million and negative EPS of $0.25 for Q3 2026. The company held $53.5 million in cash and $30.1 million in short-term investments as of September 30, 2026, with a current ratio of 1.51 and cash ratio of 1.11. Recent developments include a strategic prioritization plan and clinical trial progress in esophageal cancer therapies [S2][N1].
The company’s clinical trial results showing promising response rates in esophageal cancer and ongoing strategic prioritization efforts indicate focused resource allocation. Its liquidity position supports continued development activities. The initiation of combination therapy trials and special dividend issuance related to biosimilar CVRs reflect active portfolio management and potential value realization.
Coherus Oncology has reported consistent net losses and negative earnings per share in recent quarters, with revenues lagging expectations. The company’s liquidity, while sufficient for near-term operations, may require additional financing for sustained development. Clinical trial outcomes remain uncertain, and the company faces risks typical of biopharmaceutical development including regulatory, competitive, and market adoption challenges.
Coherus Oncology's moat is primarily based on its clinical development pipeline in oncology, including proprietary immuno-oncology therapies and biosimilar products. The company’s clinical trial data, such as high response rates in esophageal cancer studies, contribute to its competitive positioning. However, as a development-stage biopharmaceutical company with no reported recent revenues, its moat depends heavily on successful clinical and regulatory milestones and the ability to commercialize products.
• Clinical Development Risk: The company’s future depends on successful clinical trial outcomes and regulatory approvals, which are inherently uncertain and may delay or prevent product commercialization.
• Financial Risk: Continued net losses and negative cash flow require the company to manage liquidity carefully and potentially raise additional capital, which could dilute shareholders or increase debt.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive with rapid innovation; failure to differentiate or commercialize products effectively could impact long-term viability.
Business trends: Continued focus on oncology clinical development with emphasis on esophageal cancer therapies and strategic portfolio prioritization.
Execution milestones: Advancement of clinical trials including Phase 1 combination studies and interim clinical data releases; management of liquidity and capital structure.
Key risks: Clinical trial and regulatory uncertainties, ongoing net losses requiring capital management, and competitive pressures in oncology therapeutics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Coherus Oncology, Inc. is a biopharmaceutical company focused on oncology.
- The company reported a net loss of $39.3 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.25 per share as per its 10-Q filing dated November 9, 2026 [S2].
- As of September 30, 2026, Coherus Oncology had cash and cash equivalents of approximately $53.5 million and short-term investments of about $30.1 million, totaling $83.6 million in liquid assets [S2].
- The company’s current assets were $114.1 million and current liabilities were $75.6 million as of September 30, 2026, resulting in a current ratio of 1.51 and a cash ratio of 1.11, indicating moderate liquidity [S2].
- Coherus Oncology reported zero revenue in its 2018 annual filing, but recent news indicates ongoing clinical development and strategic prioritization efforts [S1][N1].
- Recent news highlights include the announcement of a strategic prioritization plan alongside third quarter 2026 financial results [N1].
- The company has reported losses in recent quarters including Q1, Q2, and Q3 2026, with revenue below expectations in these periods [N2][N7][N8].
- Coherus Oncology is advancing clinical trials, including a Phase 1 trial of ZM008 and LOQTORZI combination with Zumutor [N7].
- Clinical data releases include a 75% confirmed overall response rate (ORR) in first-line esophageal squamous cell carcinoma (ESCC) patients from Tagmokitug interim data and an 89% response rate in early ESCC studies [N1].
- The company has issued a special dividend related to biosimilar contingent value rights (CVRs) [N6].
Generated 2026-11-10
- N7
- N8
- S1 | 2026-03-09 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Coherus Oncology, Inc. Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan | https://www.nasdaq.com/articles/coherus-oncology-inc-reports-third-quarter-2026-financial-results-and-announces-strategic
- N2 | 2026-11-09 | www.nasdaq.com | Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/coherus-oncology-chrs-reports-q3-loss-lags-revenue-estimates
- N3 | 2026-11-06 | www.nasdaq.com | CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/camp4-therapeutics-corporation-camp-reports-q3-loss-misses-revenue-estimates
- N4 | 2026-11-04 | www.nasdaq.com | Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline | https://www.nasdaq.com/articles/earnings-preview-cormedix-crmd-q3-earnings-expected-decline
- N5 | 2026-11-02 | www.nasdaq.com | Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know | https://www.nasdaq.com/articles/will-coherus-oncology-chrs-report-negative-earnings-next-week-what-you-should-know
- N6 | 2026-08-18 | www.nasdaq.com | Coherus Oncology Jumps On Special Dividend Of Biosimilar CVRs | https://www.nasdaq.com/articles/coherus-oncology-jumps-special-dividend-biosimilar-cvrs
- N7 | 2026-08-13 | www.nasdaq.com | Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/coherus-oncology-chrs-q2-2026-earnings-call-transcript
- N8 | 2026-08-06 | www.nasdaq.com | Coherus Oncology Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/coherus-oncology-q2-earnings-call-highlights
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


